Delova Biotech

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s Category 2 drug QP001 in mainland China via a licensing deal. QP001, a nonsteroidal anti-inflammatory drug (NSAID), is a me-better version of Boehringer Ingelheim’s Mobic (meloxicam) and is awaiting regulatory decisions in China and the…